Mevox utilizes molecular characterization and structure-based design to create conformationally precise protein antigens that induce significantly higher neutralizing antibody levels compared to existing vaccines. This technology addresses the need for more effective vaccines that provide durable immunity and improved protection against infectious diseases.
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current vaccine technologies often fail to elicit sufficiently high levels of neutralizing antibodies, resulting in limited protection and/or short-lived immunity against infectious diseases. This necessitates the development of novel vaccine approaches that can induce robust and durable immune responses.
Solution
MEVOX is developing conformationally precise protein antigens using molecular characterization and structure-based design to create optimized vaccines. This approach aims to induce significantly higher levels of neutralizing antibodies compared to existing vaccines, leading to sterilizing and durable immunity. By combining in-house expertise with partnerships in antigen design and vaccine development, MEVOX seeks to address unmet needs in vaccinology and improve global health outcomes. The company leverages cutting-edge vaccine innovation and translational expertise to bring established vaccines into the 21st century.
Target Audience
The primary target audience includes global health organizations, pharmaceutical companies, and government agencies seeking improved vaccine technologies for infectious disease prevention.
Features
- Structure-based antigen design for conformationally precise protein antigens
- Molecular characterization to optimize immunogenicity
- Vaccine engineering to improve safety and producibility
- Induction of 10-100 times higher neutralizing antibody levels compared to existing vaccines
- Partnerships with world leaders in antigen design and disease targets